Biomerica Incorporated (NASDAQ:BMRA)’s Stock Is Sell After More Market Selling

September 17, 2017 - By Marry Poplack

 Biomerica Incorporated (NASDAQ:BMRA)'s Stock Is Sell After More Market Selling

The stock of Biomerica Incorporated (NASDAQ:BMRA) registered an increase of 60% in short interest. BMRA’s total short interest was 800 shares in September as published by FINRA. Its up 60% from 500 shares, reported previously. With 6,200 shares average volume, it will take short sellers 0 days to cover their BMRA’s short positions. The short interest to Biomerica Incorporated’s float is 0.01%.

The stock decreased 1.07% or $0.03 on September 15, reaching $2.78. About 13,027 shares traded or 26.93% up from the average. Biomerica, Inc. (NASDAQ:BMRA) has risen 66.46% since September 17, 2016 and is uptrending. It has outperformed by 49.76% the S&P500.

Biomerica, Inc. is a biomedical company, which develops, makes and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company has market cap of $23.66 million. The Company’s medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care . It currently has negative earnings. The Firm operates in Europe, the United States, Asia, South America, the Middle East and other foreign countries.

More notable recent Biomerica, Inc. (NASDAQ:BMRA) news were published by: which released: “Biomerica Announces Fiscal Year End 2017 Financial Results; Sales Up 12.7% for …” on August 30, 2017, also with their article: “Biomerica Commences Clinical Studies for New Gastroenterology H. Pylori Test” published on September 12, 2017, published: “BRIEF-Biomerica commences clinical studies for new Gastroenterology H. Pylori test” on September 12, 2017. More interesting news about Biomerica, Inc. (NASDAQ:BMRA) were released by: and their article: “Biomerica Announces Point of Care Product Distribution Agreement with a …” published on August 16, 2017 as well as‘s news article titled: “Biomerica: The Next Major IBS Product” with publication date: September 02, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.